Tirzepatide
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly · Phase 3 · Completed · Enrollment 441
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Tirzepatide 5 milligram (mg) | n/r | n/r | n/r | n/r | n/r |
| Tirzepatide Maximum Tolerated Dose | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.